Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endosonography | 19 | 2018 | 56 | 3.550 |
Why?
|
| Adenocarcinoma | 10 | 2010 | 315 | 1.230 |
Why?
|
| Pancreatic Neoplasms | 7 | 2006 | 142 | 1.060 |
Why?
|
| Biliary Tract | 2 | 2012 | 7 | 0.780 |
Why?
|
| Biliary Tract Diseases | 2 | 2012 | 12 | 0.770 |
Why?
|
| Cholestasis | 2 | 2012 | 18 | 0.750 |
Why?
|
| Pancreatic Cyst | 3 | 2018 | 4 | 0.690 |
Why?
|
| Biopsy, Fine-Needle | 6 | 2009 | 53 | 0.640 |
Why?
|
| Incidental Findings | 1 | 2017 | 27 | 0.590 |
Why?
|
| Digestive System Diseases | 1 | 2016 | 6 | 0.560 |
Why?
|
| Lymphatic Diseases | 2 | 2012 | 10 | 0.500 |
Why?
|
| Lymph Nodes | 2 | 2012 | 106 | 0.470 |
Why?
|
| Endoscopy, Gastrointestinal | 4 | 2018 | 25 | 0.430 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 518 | 0.420 |
Why?
|
| Pancreatitis, Acute Necrotizing | 2 | 2018 | 6 | 0.410 |
Why?
|
| Humans | 39 | 2018 | 32297 | 0.380 |
Why?
|
| Colonoscopy | 2 | 2018 | 45 | 0.360 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2010 | 5 | 0.360 |
Why?
|
| Gastrostomy | 1 | 2010 | 17 | 0.360 |
Why?
|
| Retrospective Studies | 11 | 2018 | 3514 | 0.350 |
Why?
|
| Sensitivity and Specificity | 6 | 2012 | 600 | 0.330 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2008 | 12 | 0.330 |
Why?
|
| Liver Diseases | 1 | 2009 | 70 | 0.320 |
Why?
|
| Pancreatitis, Chronic | 3 | 2016 | 9 | 0.300 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 4 | 2016 | 33 | 0.300 |
Why?
|
| Appendiceal Neoplasms | 1 | 2008 | 98 | 0.290 |
Why?
|
| Female | 25 | 2018 | 20126 | 0.290 |
Why?
|
| Esophageal Neoplasms | 4 | 2010 | 35 | 0.290 |
Why?
|
| Male | 23 | 2018 | 19488 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2010 | 462 | 0.280 |
Why?
|
| Middle Aged | 20 | 2018 | 11949 | 0.280 |
Why?
|
| Liver | 2 | 2009 | 486 | 0.280 |
Why?
|
| Adult | 16 | 2018 | 9467 | 0.280 |
Why?
|
| Telomerase | 1 | 2006 | 22 | 0.270 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 2296 | 0.270 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 56 | 0.270 |
Why?
|
| Aged | 16 | 2018 | 10398 | 0.270 |
Why?
|
| Peritoneal Neoplasms | 1 | 2008 | 263 | 0.260 |
Why?
|
| DNA | 1 | 2006 | 229 | 0.250 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2016 | 18 | 0.230 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2010 | 56 | 0.220 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2003 | 103 | 0.220 |
Why?
|
| Hepatitis C | 1 | 2003 | 41 | 0.220 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 525 | 0.210 |
Why?
|
| Veterans | 1 | 2003 | 66 | 0.210 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 4050 | 0.200 |
Why?
|
| Necrosis | 1 | 2018 | 56 | 0.160 |
Why?
|
| Pancreatectomy | 1 | 2018 | 32 | 0.160 |
Why?
|
| Journal Impact Factor | 1 | 2018 | 11 | 0.160 |
Why?
|
| Antineoplastic Agents | 1 | 2003 | 611 | 0.160 |
Why?
|
| Deoxycytidine | 3 | 2010 | 68 | 0.160 |
Why?
|
| Pancreatitis | 3 | 2011 | 22 | 0.150 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 877 | 0.150 |
Why?
|
| Curriculum | 2 | 2012 | 210 | 0.150 |
Why?
|
| Radiopharmaceuticals | 3 | 2010 | 94 | 0.150 |
Why?
|
| Pancreas | 4 | 2010 | 104 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 160 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 101 | 0.140 |
Why?
|
| Choledocholithiasis | 1 | 2016 | 3 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2017 | 116 | 0.140 |
Why?
|
| Self Concept | 1 | 2016 | 42 | 0.140 |
Why?
|
| Intraoperative Care | 1 | 2016 | 49 | 0.140 |
Why?
|
| Needles | 1 | 2016 | 31 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 258 | 0.130 |
Why?
|
| Colonic Polyps | 2 | 2018 | 15 | 0.120 |
Why?
|
| Esophagectomy | 2 | 2010 | 15 | 0.110 |
Why?
|
| Prognosis | 1 | 2017 | 1523 | 0.110 |
Why?
|
| Abdomen | 1 | 2012 | 45 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2016 | 1281 | 0.100 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 53 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 77 | 0.100 |
Why?
|
| Child | 2 | 2016 | 2472 | 0.100 |
Why?
|
| Positron-Emission Tomography | 2 | 2010 | 190 | 0.100 |
Why?
|
| Cholelithiasis | 1 | 2011 | 12 | 0.100 |
Why?
|
| Combined Modality Therapy | 6 | 2011 | 567 | 0.090 |
Why?
|
| Comorbidity | 2 | 2011 | 572 | 0.090 |
Why?
|
| Adolescent | 2 | 2016 | 3571 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2016 | 2274 | 0.090 |
Why?
|
| Quality of Life | 1 | 2016 | 915 | 0.090 |
Why?
|
| Young Adult | 1 | 2017 | 2626 | 0.090 |
Why?
|
| Catheterization | 1 | 2010 | 59 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 545 | 0.090 |
Why?
|
| Gallbladder Neoplasms | 1 | 2009 | 36 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 696 | 0.080 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 36 | 0.080 |
Why?
|
| Survival Rate | 3 | 2006 | 894 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 279 | 0.080 |
Why?
|
| Radiography | 1 | 2009 | 377 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 217 | 0.070 |
Why?
|
| Forecasting | 1 | 2008 | 145 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 159 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2007 | 331 | 0.070 |
Why?
|
| Genes, ras | 1 | 2006 | 25 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2009 | 201 | 0.070 |
Why?
|
| False Positive Reactions | 1 | 2006 | 31 | 0.070 |
Why?
|
| Celiac Plexus | 1 | 2006 | 3 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 49 | 0.070 |
Why?
|
| Disease Progression | 2 | 2006 | 618 | 0.070 |
Why?
|
| Bile Duct Diseases | 1 | 2006 | 10 | 0.070 |
Why?
|
| Nerve Block | 1 | 2006 | 51 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2006 | 67 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 190 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2009 | 1447 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 32 | 0.070 |
Why?
|
| Vomiting | 1 | 2005 | 25 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 1522 | 0.060 |
Why?
|
| Camptothecin | 1 | 2005 | 53 | 0.060 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2005 | 2 | 0.060 |
Why?
|
| Education, Medical | 1 | 2006 | 70 | 0.060 |
Why?
|
| Colchicine | 1 | 2005 | 8 | 0.060 |
Why?
|
| Nausea | 1 | 2005 | 54 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 43 | 0.060 |
Why?
|
| Diarrhea | 1 | 2005 | 60 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2005 | 45 | 0.060 |
Why?
|
| Fatigue | 1 | 2005 | 85 | 0.060 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 18 | 0.060 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 320 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 926 | 0.060 |
Why?
|
| Cholangiography | 2 | 2016 | 11 | 0.060 |
Why?
|
| Mutation | 1 | 2006 | 503 | 0.060 |
Why?
|
| Genes, erbB-1 | 1 | 2003 | 15 | 0.060 |
Why?
|
| Pain | 1 | 2006 | 305 | 0.060 |
Why?
|
| Diphtheria Toxin | 1 | 2003 | 23 | 0.060 |
Why?
|
| Radiotherapy Dosage | 3 | 2010 | 101 | 0.060 |
Why?
|
| Injections | 1 | 2003 | 65 | 0.060 |
Why?
|
| Georgia | 1 | 2003 | 14 | 0.060 |
Why?
|
| Angioedema | 1 | 2003 | 3 | 0.060 |
Why?
|
| Viscera | 1 | 2003 | 17 | 0.060 |
Why?
|
| Enalapril | 1 | 2003 | 8 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2007 | 306 | 0.060 |
Why?
|
| Florida | 1 | 2003 | 37 | 0.060 |
Why?
|
| Prisoners | 1 | 2003 | 11 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2018 | 3358 | 0.060 |
Why?
|
| Hospitals, Veterans | 1 | 2003 | 38 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2010 | 459 | 0.050 |
Why?
|
| Stomach Diseases | 1 | 2002 | 7 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2010 | 191 | 0.050 |
Why?
|
| Choristoma | 1 | 2002 | 18 | 0.050 |
Why?
|
| Cell Survival | 1 | 2003 | 301 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 98 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 141 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2002 | 67 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2003 | 179 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2003 | 124 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 422 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2003 | 736 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2016 | 550 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 779 | 0.040 |
Why?
|
| Disinfection | 1 | 2018 | 5 | 0.040 |
Why?
|
| Barrett Esophagus | 1 | 2018 | 3 | 0.040 |
Why?
|
| Equipment Contamination | 1 | 2018 | 11 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 67 | 0.040 |
Why?
|
| False Negative Reactions | 2 | 2011 | 22 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 29 | 0.040 |
Why?
|
| Adenoma | 1 | 2018 | 39 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2018 | 56 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2009 | 1832 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2011 | 920 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2018 | 197 | 0.040 |
Why?
|
| Disease Management | 1 | 2018 | 131 | 0.040 |
Why?
|
| Length of Stay | 1 | 2018 | 315 | 0.040 |
Why?
|
| Stents | 1 | 2018 | 180 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 75 | 0.030 |
Why?
|
| Videotape Recording | 1 | 2016 | 13 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 61 | 0.030 |
Why?
|
| United States | 2 | 2018 | 3983 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 222 | 0.030 |
Why?
|
| Psychometrics | 1 | 2016 | 137 | 0.030 |
Why?
|
| Risk Factors | 1 | 2003 | 3876 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2006 | 154 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2005 | 491 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2005 | 406 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 57 | 0.030 |
Why?
|
| Animals | 1 | 2003 | 7694 | 0.020 |
Why?
|
| Cholagogues and Choleretics | 1 | 2011 | 3 | 0.020 |
Why?
|
| Technetium Tc 99m Lidofenin | 1 | 2011 | 3 | 0.020 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2011 | 4 | 0.020 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2011 | 8 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 2011 | 12 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2011 | 38 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 37 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2010 | 3 | 0.020 |
Why?
|
| Age of Onset | 1 | 2011 | 100 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 84 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2010 | 67 | 0.020 |
Why?
|
| Obesity | 1 | 2018 | 1164 | 0.020 |
Why?
|
| Medical Records | 1 | 2010 | 77 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2011 | 100 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 82 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 140 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 109 | 0.020 |
Why?
|
| Video Recording | 1 | 2010 | 57 | 0.020 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2009 | 4 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 32 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 160 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 150 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2009 | 114 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 2007 | 24 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2007 | 42 | 0.020 |
Why?
|
| Anesthesia | 1 | 2007 | 64 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 79 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 13 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2005 | 23 | 0.020 |
Why?
|
| Recurrence | 1 | 2006 | 266 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 788 | 0.020 |
Why?
|
| Morbidity | 1 | 2005 | 98 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2005 | 171 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 675 | 0.020 |
Why?
|
| Mediastinum | 1 | 2004 | 14 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 302 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2004 | 61 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 370 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 398 | 0.010 |
Why?
|
| Ethnic Groups | 1 | 2006 | 480 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 410 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2002 | 171 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 497 | 0.010 |
Why?
|
| Hypertension | 1 | 2003 | 972 | 0.010 |
Why?
|